Skip to content

A Study on the safety of inflatable subxiphatic thoracoscopic mediastinal tumor resection compared with double-suspension retractor surgery in primary hospitals

A Study on the safety of inflatable subxiphatic thoracoscopic mediastinal tumor resection compared with double-suspension retractor surgery in primary hospitals

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105057
Enrollment
Unknown
Registered
2025-06-27
Start date
2024-03-23
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mediastinal tumor

Interventions

Surgery Group A(Inflatable subxiphoid thoracoscopic mediastinal tumor resection):None
Surgery Group B(Double sling retractor mediastinal tumor resection):None

Sponsors

Department of thoracic surgery,jiangsu shengze hospital affiliated to nanjing medical university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Preoperative chest CT indicates anterior superior mediastinal tumor or space-occupying lesion, with or without myasthenia gravis, considered benign or early malignant, no organ metastasis or severe invasion of surrounding tissues; 2. Aged 18 - 75 years, no previous radiotherapy, chemotherapy, or targeted drug therapy; 3. Tolerable to general anesthesia; 4. No severe diseases in heart, brain, liver, kidney, blood, etc; 5. No severe immune dysfunction or abuse of anticoagulants or drugs; 6.Informed consent signed by patients and their families.

Exclusion criteria

Exclusion criteria: 1. Mediastinal tumor diameter > 5 cm or preoperative chest CT assessment of tumor infiltration of surrounding large blood vessels, nerves and pericardium or organ infiltration, distant metastasis; 2. Considered as lymphoma or patients diagnosed as lymphoma by puncture biopsy; 3. Patients with anterior superior mediastinal tumors located at one side of the thoracic apex or across the thoracic inlet, where subxiphoid operation is difficult; 4. Patients with tumors involving unilateral or bilateral lung lobes simultaneously and requiring combined lobectomy; 5. Patients with autoimmune diseases and hematological diseases; 6. Poor compliance, difficult to complete treatment and follow-up; 7. History of thoracic surgery; 8. Incomplete or lost information records.

Design outcomes

Primary

MeasureTime frame
Postoperative recovery indicators;

Secondary

MeasureTime frame
Postoperative complications;Suregical larning curve;Hospitalization costs;

Countries

China

Contacts

Public ContactChangyong Yu

Jiangsu Shengze Hospital Affiliated to Nanjing Medical University

ycywyw125@126.com+86 139 1314 1941

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026